Get the Stockscreener App
1.93
1.53%
-0.03
Outlook Therapeutics Inc stock is traded at $1.93, with a volume of 669.04K.
It is down -1.53% in the last 24 hours and up +22.15% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.96
Open:
$1.95
24h Volume:
669.04K
Relative Volume:
0.86
Market Cap:
$64.79M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.4825
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-5.39%
1M Performance:
+22.15%
6M Performance:
-6.31%
1Y Performance:
-73.92%
1-Day Range:
$1.86
$1.96
1-Week Range:
$1.86
$2.135
52-Week Range:
$0.87
$8.32
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.93 | 83.99M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - jammulinksnews.com
When is Outlook Therapeutics Inc. stock expected to show significant growth - jammulinksnews.com
What institutions are buying Outlook Therapeutics Inc. stock nowEntry Points For Growing Stocks Identified by Models - metal.it
Ichimoku Cloud Indicates Uncertainty Around Outlook Therapeutics Inc.Real Trader Watchlist of Hot Stocks Released - metal.it
What caused OTLK's net profit surge in Q3 2024? - AInvest
How does Outlook Therapeutics Inc. generate profit in a changing economyEntry Signal Planner To Watch Now - jammulinksnews.com
How volatile is Outlook Therapeutics Inc. stock compared to the marketBeginner Investor Tips For 2025 - jammulinksnews.com
What institutional investors are buying Outlook Therapeutics Inc. stockPost Market Watchlist For Every Investor - jammulinksnews.com
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsInvest confidently with professional market insights - jammulinksnews.com
How many analysts rate Outlook Therapeutics Inc. as a “Buy”Build your wealth with consistent stock growth - jammulinksnews.com
Outlook Therapeutics Inc. stock outlook for YEAR Pattern Recognition Based Market Move Prediction - Newser
Why is Outlook Therapeutics Inc. stock attracting strong analyst attentionInvest confidently with professional market insights - jammulinksnews.com
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Unlock powerful market trend analysis - jammulinksnews.com
Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - jammulinksnews.com
What makes Outlook Therapeutics Inc. stock price move sharplySecure Your Capital Strategy - metal.it
How strong is Outlook Therapeutics Inc. company’s balance sheetInvest smarter with data-backed trading alerts - jammulinksnews.com
Published on: 2025-07-28 00:00:40 - jammulinksnews.com
Top Risks to Consider Before Buying Outlook Therapeutics Inc. StockSafe High Return Entry Points - Newser
Outlook Therapeutics Inc. Stock Support and Resistance Levels You Should KnowBig Return Stock Tips - Newser
Why Outlook Therapeutics Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
Outlook Therapeutics, Inc. shares fall 2.45% after-hours amid mixed market sentiment. - AInvest
What analysts say about Outlook Therapeutics Inc. stockPowerful growth strategies - PrintWeekIndia
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Outlook Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - PrintWeekIndia
Outlook Therapeutics to Present at the 8th Annual Ophthalmology - GuruFocus
Outlook Therapeutics Showcases Breakthrough Retina Treatment Innovation at Elite Ophthalmology Summit - Stock Titan
What drives Outlook Therapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Outlook Therapeutics Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment - Stock Titan
Is Outlook Therapeutics Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):